[ASC-media] Media Alert: Innovative Technology to fast track Stem Cell Therapy in Australia - Stem Cell Workshop in Sydney Friday
skirk at iprimus.com.au
Tue Nov 26 17:00:04 PST 2013
Oh how I love that we are embracing the argument around stem cell therapy.
I¹m green and on the fence.
On 27/11/13 10:23 AM, "Daniella Goldberg (Gene Genie Media)"
<daniella at genegeniemedia.com.au> wrote:
> When will patients benefit from stem cell therapy in Australia?
> - The challenges of taking stem cells from the lab to the clinic -
> SYDNEY, AUSTRALIA, Tuesday 26 November 2013 Australian stem cell experts are
> joining forces to address the future of stem cell research in Australia and
> the critical gap in taking innovative stem cell therapies from the laboratory
> to patients in the clinic.
> Over 100 clinicians, scientists, policy makers, investors, IP lawyers, patient
> advocates, pharma and biotech executives are participating in the Workshop -
> Innovating the Marketplace with Stem Cells - hosted by the NSW Stem Cell
> Network to take a serious look at this vital issue facing Australia¹s stem
> cell industry.
> Professor Bernie Tuch, Founder and Director of the NSW Stem Cell Network said
> that Australia is the birth place of innovative ideas in stem cell research
> and therapies and has demonstrated commercial success as the birthplace of the
> world¹s biggest stem cell company, Mesoblast (ASX:MSB) and world leading IVF
> clinic Genea. Clinically we also have some of the most innovative research
> including success in clinical trials for stem cell treatment of a corneal eye
> disease at University of NSW and for treatment resistant Crohn¹s disease at
> the University of Western Australia.
> In light of these successes, the Australian industry is plagued by a loss of
> our IP, talent and manufacture to countries abroad, that are better supported
> with commercialisation and investment opportunities.
> A collective effort is needed to push this industry forward. Basic
> researchers need to become educated as to the part they play in getting their
> technology to patients and interactions need to improve between Australia¹s
> researchers, clinicians, commercial and regulatory bodies towards driving
> realistic solutions.¹
> The US, Switzerland, Germany, the UK, many countries are currently running
> clinical trials for which we have the expertise in Australia, many even
> utilise Australian technologies. We cannot miss the chance to lead this
> industry by sitting back and waiting¹, said Professor Tuch.
> Key-note speaker, Professor Igor Slukvin, University Wisconsin-Madison will be
> presenting a new stem cell technology, CymerusTM, which has the potential to
> manufacture billions of human Mesenchymal stem cells from a single embryonic
> stem cell and poses great therapeutic for patients.
> Dr Slukvin invented his technology in Wisconsinlaboratory alongside Professor
> James Thomson, who is well-known for creating the world¹s first embryonic stem
> (ES) cell line in 1998 and human induced pluripotent stem cells in 2007.
> ³Stem cell therapy has not taken the path that scientists predicted over ten
> years ago. We have found only one type of stem cell, The Mesenchymal stem
> cell show great promise and is ready for clinical trial for a broad range of
> diseasesright now,² says Dr Slukvin.
> Mesenchymal stem cells works by stimulating thebody¹s own healing systems and
> have the potential to remedy a broad range of diseases including
> cardiovascular disease, diabetes, diseases of the blood,lung, kidney, eyes
> teeth and immune system diseases.
> Dr Paul Brock who has Motor Neurone Disease and is a long time advocate of
> stem cell technologies in Australia says, ³I have been disappointed at what
> has appeared to me to have been the slow take up of Australian research
> projects utilising the legislative green light given toembryonic stem cell
> research and somatic cell nuclear transfer research by those Bills.²
> However he is confident that effectively resourced, internationally
> collaborative stem cell research, thriving within a multidisciplinary
> cross-siloed scientific approach to ultimately producing successful
> therapeutic outcomes, will play a vital role in better understanding the
> causes of and eventually developing cures for currently incurable, terminal
> neurological diseases such as MotorNeurone Disease¹
> Recent activity in Australian stem cell research and industry indicates that
> if properly supported this slow up take is about to change.
> Media Contact
> Daniella Goldberg PhD, Gene Genie Media: Tel: 0416 211 067 eml:
> Daniella at genegeniemedia.com.au
> ASC-media mailing list
> media at asc.asn.au
-------------- next part --------------
An HTML attachment was scrubbed...
-------------- next part --------------
A non-text attachment was scrubbed...
Size: 50036 bytes
Desc: not available
More information about the ASC-media